Sunovion Pharmaceuticals Inc.
Sunovion Pharmaceuticals Inc. is a research-based pharmaceutical company dedicated to discovering, developing and commercializing scientifically advanced therapeutic products that are focused on helping patients suffering from central nervous system and respiratory disorders, as well as other illnesses.
Sunovion, a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., was formed following the merger of Sumitomo Dainippon Pharma's two U.S.-based operations, Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc. The company name, which is representative of the strength of the sun with innovation, reflects Sunovion's portfolio of currently marketed pharmaceutical products and pipeline candidates; and serves to emphasize the company's ongoing commitment to improve the lives of patients everywhere.
|Business||Manufacturing and sales of pharmaceuticals|
|Address||84 Waterford Drive Marlborough, MA 01752|
|Major pharmaceutical products||Therapeutic indication|
|UTIBRON™ NEOHALER®||Long-acting muscarinic antagonist/
Long-acting beta2 agonist
|SEEBRI™ NEOHALER®||Long-acting muscarinic antagonist|
|ARCAPTA® NEOHALER®||Long-acting beta2 agonist|
|BROVANA®||Long-acting beta2 agonist|
|XOPENEX HFA®||Short-acting beta agonist|